1. To discuss female specific factors such as pre-eclampsia and early menopause that are “risk-enhancers” that
increase CVD risk in women and how to incorporate these factors into shared-decision making with patients
about preventive therapies.
2. To review the prognostic impact of subclinical atherosclerosis and non-obstructive coronary artery disease on
women’s future ASCVD risk and opportunities to enhance prevention.
3. To review disparities in enrollment of women patients into cardiovascular clinical trials and discuss
suggestions for improvement in this area.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation